Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
Phase 1/2 Completed
34 enrolled 22 charts
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
Phase 2 Completed
73 enrolled 16 charts
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Phase 2 Completed
60 enrolled 10 charts
MOHEL
Phase 2 Completed
46 enrolled 12 charts
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 1/2 Withdrawn
Cyclophosphamide and Alemtuzumab In Lymphoma
Phase 1 Terminated
3 enrolled
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
Phase NA Terminated
19 enrolled
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
12 enrolled 10 charts
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
Phase 1 Completed
24 enrolled
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
Phase 2 Completed
25 enrolled
REGALE
Phase NA Terminated
24 enrolled 7 charts
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
Phase 2 Completed
2 enrolled
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2 Terminated
36 enrolled 16 charts
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 2 Completed
51 enrolled 11 charts
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
Phase 1/2 Completed
24 enrolled
Campath-1H + FK506 and Methylprednisolone for GVHD
Phase 2 Completed
34 enrolled
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Phase 2 Completed
53 enrolled
Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma
Phase 1 Completed